Tarlatamab

Buy Tarlatamab (Imdelltra) Online in India
Generic Name/API:Tarlatamab- dlle
Packaging:1vial / pack
Storage:2°C to 8°C & 20°C to 25°C
Dosage:For dosage information, please check the General Information section.
Strength:1 mg package contains 1 single-dose vial of 1 mg IMDELLTRA and 2 vials of 7 mL IV Solution Stabilizer. 10 mg package contains 1 single-dose vial of 10 mg IMDELLTRA and 2 vials of 7 mL IV Solution Stabilizer
Indication:IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 Tcell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy

Imdelltra (tarlatamab) is an innovative bispecific T-cell engager approved for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Administered as an intravenous infusion, IMDELLTRA works by simultaneously binding to DLL3 (Delta-like ligand 3), a protein highly expressed on the surface of SCLC tumor cells, and CD3, a receptor on the surface of T-cells.

DOSAGE:  

Dosing Schedule   Day  Dosage of Imdelltra Administration Instructions Recommended Monitoring  
Step-up Dosing Schedule Cycle 1 Day 1

Day 8

Day 15

Step-up doses 1 mg

10mg

10mg

Administer IMDELLTRA as a 1-hour intravenous infusion in an appropriate healthcare setting.  

Monitor patients from the start of the IMDELLTRA infusion for 22 to 24 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Recommend that patients remain within 1-hour of an appropriate healthcare setting for a total of 48 hours from start of the infusion with IMDELLTRA, accompanied by a caregiver.

Observe patients for 6-8 hours post IMDELLTRA infusion .
Cycle 2  Day 1 and 15  

10mg

 Observe patients for 6-8 hours post IMDELLTRA infusion
Cycles 3 and 4  Day 1 and 15

10mg

 Observe patients for 3-4 hours post IMDELLTRA infusion
Cycle 5 and subsequent infusions  Day 1 and 15 10mg Observe patients for 2 hours post IMDELLTRA infusion

ADVERSE REACTIONS:

  • Cytokine Release Syndrome (CRS), 
  • Fatigue, fever, dysgeusia, nausea, constipation, arthralgia, decreased appetite, and rash. 
  • Other frequent side effects include edema, headache, cough, and diarrhea. Laboratory abnormalities such as decreases in lymphocytes, phosphorus, creatine, and increases in aspartate aminotransferase (AST) are also commonly observed.

SIDE EFFECTS:

  • Cytokine release syndrome (CRS). This can manifest as fever, chills, rapid heart rate, low blood pressure, and difficulty breathing, necessitating prompt medical attention. 
  • Neurological side effects, such as peripheral neuropathy (numbness or tingling in the hands and feet), dizziness, or confusion, are also a possibility and require vigilance. 
  • Additionally, patients may experience hematologic toxicities like anemia, low white blood cell counts, and low platelet counts, increasing the risk of infection and bleeding

STORAGE :

  • 2°C to 8°C & 20°C to 25°C
  • Cytokine Release Syndrome (CRS) and Neurologic Toxicity (including Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS), both of which can be severe or life-threatening.
  • Other important warnings include the risk of serious infections due to immune system effects, hepatotoxicity, and embryo-fetal toxicity

Process to Import Medicine

FAQ

IMDELLTRA is used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has progressed after receiving platinum-based chemotherapy.

It’s an immunotherapy called a bispecific T-cell engager. It works by bringing your body’s T-cells (a type of immune cell) close to the cancer cells, activating the T-cells to identify and kill the cancer cells.

It is given as an intravenous (IV) infusion, meaning it’s put directly into your vein through a needle.

The first few doses require hospitalization and close monitoring due to the risk of serious side effects like Cytokine Release Syndrome (CRS) and neurologic toxicity, which need immediate medical attention if they occur.

The most serious side effects are Cytokine Release Syndrome (CRS) and specific neurologic toxicities (ICANS), which can be severe or life-threatening. Your care team will monitor you closely for these.

No, IMDELLTRA can harm an unborn baby. Women who can become pregnant must use effective birth control during treatment and for a specified period after the last dose.

Inform your doctor about all your medical conditions, including any history of neurologic problems, infections, liver problems, or if you are pregnant, planning to become pregnant, or breastfeeding. Also, list all medications you are taking, including prescription, over-the-counter, vitamins, and herbal supplements.

Treatment typically continues as long as your cancer is responding to the medication and you are not experiencing unacceptable side effects. Your doctor will determine the duration of treatment.

Immediately report any signs of fever, chills, confusion, difficulty speaking, severe headache, seizures, weakness, or significant changes in your thinking or behavior, as these could be symptoms of CRS or neurologic toxicity.

The cost of Imdelltra (Tarlatamab) in India varies since it is not widely marketed locally and must be imported. Supplier availability, import duties, and currency fluctuations affect the final price. For the pricing details, contact 24/7QualityMeds at +91 9967979080.

To buy Imdelltra (Tarlatamab) injection in India at a genuine price, contact 24/7QualityMeds. We assist with prescription verification, import documentation, sourcing from certified suppliers, and ensure secure delivery.

Related products